저자(한글) |
김솔잎,윤여민,김인숙,송상훈,우혜인,이경아,이우창,조현정,지미숙,채효진,이수연,전사일,인제대학교 의과대학 일산백병원 진단검사의학과,건국대학교 의학전문대학원 진단검사의학교실,부산대학교 의과대학 진단검사의학교실,서울대학교병원 진단검사의학과,성균관대학교,연세대학교,울산대학교,건양대학교 의과대학 진단검사의학교실,중앙보훈병원 진단검사의학과,가톨릭대학교,성균관대학교 |
초록 |
Pharmacogenetics is a rapidly evolving field and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation of pharmacogenetic tests in clinical practice may result in a rise in medical costs and adverse outcomes in patients. This document suggests guidelines for the clinical application, interpretation, and reporting of pharmacogenetic test results based on a literature review and the collection of evidence-based expert opinions. The clinical laboratory practice guidelines encompass the clinical pharmacogenetic tests covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic tests have also been addressed. In particular, this document comprises the following pharmacogenetic tests: CYP2C9 and VKORC1 for warfarin, CYP2C19 for clopidogrel, CYP2D6 for tricyclic antidepressants, codeine, tamoxifen, and atomoxetine, NAT2 for isoniazid, UGT1A1 for irinotecan, TPMT for thiopurines, EGFR for tyrosine kinase inhibitors, ERBB2 (HER2) for erb-b2 receptor tyrosine kinase 2-targeted therapy, and KRAS for anti-epidermal growth factor receptor drugs. These guidelines would help improve the usefulness of pharmacogenetic tests in routine clinical settings. |